Uploaded October 2026 | Updated November 2026, 3 hours ago
SandboxAQ CEO Jack Hidary and NVIDIA’s Head of BD for BioPharma Labs & Manufacturing Stacie Calad-Thomson host a roundtable at TechCrunch Disrupt on what comes after LLMs: Large Quantitative Models (LQMs) and the rise of physical AI.
In this interactive session, Jack and Stacie explore how the combination of LLMs (as a conversational interface) and Large Quantitative Models (as the physics and math engines) are creating the next massive leap in AI for healthcare, energy, aerospace, and financial services.
Timestamps:
0:00 - Introduction: The Limits of Language Models
3:47 - Exploring the "Modern AI Stack" for R&D
5:28 - What are Large Quantitative Models (LQMs)?
8:50 - The Hallucination Problem: Why Physical AI Requires Total Accuracy
15:15 - Audience Q&A: World Models and Robotics
18:40 - Audience Q&A: Aerospace, Materials Science & Crashworthiness
22:28 - Audience Q&A: Expanding AI into IoT and Smart Devices
24:42 - Audience Q&A: Biopharma & Expanding The Drug Discovery Design Space
27:31 - Audience Q&A: Transition to LQMs in Financial Markets
SandboxAQ CEO Jack Hidary and NVIDIA’s Head of BD for BioPharma Labs & Manufacturing Stacie Calad-Thomson host a roundtable at TechCrunch Disrupt on what comes after LLMs: Large Quantitative Models (LQMs) and the rise of physical AI.
In this interactive session, Jack and Stacie explore how the combination of LLMs (as a conversational interface) and Large Quantitative Models (as the physics and math engines) are creating the next massive leap in AI for healthcare, energy, aerospace, and financial services.
Timestamps:
0:00 - Introduction: The Limits of Language Models
3:47 - Exploring the "Modern AI Stack" for R&D
5:28 - What are Large Quantitative Models (LQMs)?
8:50 - The Hallucination Problem: Why Physical AI Requires Total Accuracy
15:15 - Audience Q&A: World Models and Robotics
18:40 - Audience Q&A: Aerospace, Materials Science & Crashworthiness
22:28 - Audience Q&A: Expanding AI into IoT and Smart Devices
24:42 - Audience Q&A: Biopharma & Expanding The Drug Discovery Design Space
27:31 - Audience Q&A: Transition to LQMs in Financial Markets










